Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage...
100 insider sale filings on record · latest filing 2026-10-02.
No open-market insider purchases (SEC Form 4 code P) on record for SYRE.